Amneal Pharmaceuticals advances DHE autoinjector resubmission and secures FDA approval for exenatide

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), has achieved two significant milestones, reinforcing its position in the pharmaceutical industry. The company announced the resubmission of its New ... Read More